NCT01901133View on ClinicalTrials.gov

Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Pharmacokinetics of MDV3100Healthy SubjectsKidney Diseases
Interventions
DRUG

MDV3100

Oral

Trial Locations (1)

Unknown

Arensia, Chisinau

Sponsors

Collaborators (1)

Medivation, Inc.
All Listed Sponsors
collaborator

Medivation, Inc.

INDUSTRY

lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT01901133 - Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group | Biotech Hunter | Biotech Hunter